Clinical Trial Update: A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the effectiveness and safety of galantamine hydrobromide for cognitive impairment in schizophrenia has completed. The update summarizes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• GALANTAMINE HYDROBROMIDE (GALANTAMINE HYDROBROMIDE)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED